A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation-Reference-Cited by-同舟云学术

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Published:1999-09-17 Issue:5 Volume:44 Page:372-380
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:
Short-container-title:Cancer Chemotherapy and Pharmacology

Author:

Rinaldi David A.,Kuhn John G.,Burris Howard A.,Dorr F. Andrew,Rodriguez Gladys,Eckhardt S. Gail,Jones Suzanne,Woodworth James R.,Baker Sharyn,Langley Connie,Mascorro David,Abrahams Trent,Von Hoff Daniel D.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s002800050992.pdf

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches;Frontiers in Nephrology;2024-08-09

2. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022;International Journal of Clinical Oncology;2023-08-12

3. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial;Cancer Chemotherapy and Pharmacology;2022-11-21

4. Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study;Lung Cancer;2022-04

5. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer;Drugs;2021-12-11